Valuation: Incyte Corporation

Capitalization 19.74B 16.86B 15.45B 14.6B 27.04B 1,889B 27.18B 184B 71.61B 897B 74.08B 72.52B 3,117B P/E ratio 2026 *
15x
P/E ratio 2027 * 13x
Enterprise value 14.7B 12.56B 11.51B 10.88B 20.14B 1,407B 20.25B 137B 53.33B 668B 55.17B 54.02B 2,321B EV / Sales 2026 *
2.62x
EV / Sales 2027 * 2.08x
Free-Float
98.1%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week-1.03%
Current month+3.73%
1 month+3.42%
3 months-2.26%
6 months-6.25%
Current year+0.05%
1 week 97.07
Extreme 97.07
103.01
1 month 92.79
Extreme 92.79
103.01
Current year 89.25
Extreme 89.25
112.29
1 year 61.1
Extreme 61.105
112.29
3 years 50.27
Extreme 50.27
112.29
5 years 50.27
Extreme 50.27
112.29
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 25/06/2025
Director of Finance/CFO 57 03/05/2026
President 62 04/06/2023
Director TitleAgeSince
Chairman 59 25/06/2025
Director/Board Member 72 19/01/2015
Director/Board Member 64 19/01/2015
Change 5d. change 1-year change 3-years change Capi.($)
-0.31%-1.03%+62.51%+51.38% 19.74B
-0.49%-0.16%+25.38%-3.29% 73.24B
+0.33%+3.05%+55.73%+177.73% 53.3B
-2.29%+41.00%+41.00%+41.00% 43.78B
-1.55%-20.28%-59.44%-68.40% 34.82B
+2.59%+7.26%+66.07%-33.94% 30.2B
-5.35%+3.34%+97.80%-61.01% 20.01B
-0.40%-4.83%+73.05%+116.48% 19.29B
-0.14%-0.54%+45.52%+86.01% 16.28B
+4.03%+0.76%+106.28%+406.53% 13.44B
Average +0.18%-1.76%+51.39%+71.25% 32.41B
Weighted average by Cap. -0.17%-1.99%+41.09%+50.99%

Financials

2026 *2027 *
Net sales 5.62B 4.8B 4.4B 4.16B 7.7B 538B 7.74B 52.38B 20.39B 255B 21.09B 20.65B 887B 6.23B 5.32B 4.87B 4.61B 8.53B 596B 8.58B 58.03B 22.59B 283B 23.37B 22.88B 983B
Net income 1.38B 1.18B 1.08B 1.02B 1.89B 132B 1.9B 12.83B 4.99B 62.53B 5.17B 5.06B 217B 1.6B 1.37B 1.25B 1.18B 2.19B 153B 2.2B 14.89B 5.8B 72.6B 6B 5.87B 252B
Net Debt -5.04B -4.3B -3.94B -3.73B -6.9B -482B -6.94B -46.94B -18.27B -229B -18.9B -18.51B -795B -6.79B -5.8B -5.31B -5.02B -9.3B -650B -9.35B -63.28B -24.64B -308B -25.48B -24.95B -1,072B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
13/05/26 98.82 $ -0.31% 1,630,417
12/05/26 99.13 $ -1.19% 1,584,910
11/05/26 100.32 $ +1.79% 1,662,287
08/05/26 98.56 $ +0.81% 877,843
07/05/26 97.77 $ -2.08% 1,021,629
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
98.82USD
Average target price
108.50USD
Spread / Average Target
+9.80%

Quarterly revenue - Rate of surprise